ライフサイエンスコーパス: peptide receptor

1 f neurons that express the gastrin-releasing peptide receptor.

2 llowing recombination with an affinity clamp peptide receptor.

3 pTatC and Hcf106 is the twin arginine signal peptide receptor.

4 a melanogaster by deletion of the female sex peptide receptor.

5 or antagonist that targets gastrin-releasing peptide receptors.

6 the kappa opioid and nociceptin/orphanin FQ peptide receptors.

7 FPR1 and FPR2 as sensitive and broad signal peptide receptors.

8 Our results demonstrate that formyl peptide receptor 1 (FPR1) and neutrophilic NADPH oxidase

9 , which then induces TRMP2 binding to formyl peptide receptor 1 (FPR1) and subsequent FPR1 internaliz

10 Binding of formyl peptide receptor 1 (FPR1) by N-formyl peptides can activ

11 Formyl peptide receptor 1 (FPR1) is a G protein-coupled chemoat

12 to be described on human neutrophils, formyl peptide receptor 1 (FPR1), is one such receptor that pla

13 CXC chemokine receptor 2 (CXCR2) and formyl peptide receptor 1 (FPR1), respectively.

14 al cryosections with probes to detect formyl peptide receptor 1 (FPR1).

15 te G protein-coupled receptor relaxin family peptide receptor 1 (RXFP1), has emerged as a potential a

16 elaxin receptor, relaxin/insulin-like family peptide receptor 1 (RXFP1), in IPF fibroblasts.

17 he G protein-coupled receptor relaxin family peptide receptor 1 (RXFP1), little is known about the mo

18 f the human relaxin receptor, relaxin family peptide receptor 1 (RXFP1).

19 utic benefits of relaxin/insulin-like family peptide receptor 1 activation.

20 series of human relaxin/insulin-like family peptide receptor 1 agonists.

21 n genetic variation in the NPR1 (natriuretic peptide receptor 1 gene, encoding NPR-A, atrial natriure

22 r 1 gene, encoding NPR-A, atrial natriuretic peptide receptor 1) was recently shown to affect blood p

23 c 2), and RXFP1 (relaxin/insulin-like family peptide receptor 1).

24 m wild-type mice and mice lacking the formyl peptide receptor 1, we demonstrate that LTB(4) acts as a

25 eriments to study the capacity of the formyl peptide receptor-1 (FPR1) to desensitize chemokine recep

26 (HMGB1), respectively, as well as to formyl peptide receptor-1 (FPR1), which interacts with Annexin

27 tive properties that binds to relaxin family peptide receptor-1 (RXFP1) and has been shown to increas

28 coupled receptor for H2-RLX (relaxin family peptide receptor-1 (RXFP1)).

29 atrial/brain natriuretic peptide-natriuretic peptide receptor-1 pathway is implicated in suppressing

30 upstream of the relaxin/insulin-like family peptide receptor 2 ( RXP2) (chromosome 13, rs60249166, o

31 Activation of the G-protein coupled formyl peptide receptor 2 (ALX/FPR2) by the lipid mediators lip

32 Formyl peptide receptor 2 (FPR2) emerges as a central receptor

33 nnexin A1 (AnxA1) mainly acts through Formyl Peptide Receptor 2 (FPR2) inducing the resolution of inf

34 Formyl peptide receptor 2 (FPR2) is a chemoattractant receptor

35 Formyl peptide receptor 2 (FPR2) is a G protein-coupled pattern

36 Neutrophils expressing formyl peptide receptor 2 (FPR2) play key roles in host defense

37 The human formyl peptide receptor 2 (FPR2) plays a crucial role in host d

38 Selective agonists and antagonists of formyl peptide receptor 2 (Fpr2) suggested that Fpr2 mediated t

39 ion of a peptidomimetic antagonist of formyl peptide receptor 2 (FPR2) was explored by an approach in

40 Formyl peptide receptor 2 (FPR2), a classical chemoattractant r

41 activated the SAA1-binding receptor, formyl peptide receptor 2 (FPR2), which drove the epithelial re

42 Here we report that formyl peptide receptor 2 (Fpr2/3) null mice display a major ph

43 d activation of the human and mouse N-formyl peptide receptor 2 (huFPR2).

44 st via the natriuretic peptide C/natriuretic peptide receptor 2 (NPPC/NPR2) system, and possibly also

45 Mutations in natriuretic peptide receptor 2 (Npr2) gene cause a rare form of shor

46 e transmembrane guanylyl cyclase natriuretic peptide receptor 2 (NPR2) in response to the agonist C-t

47 s receptor, the guanylyl cyclase natriuretic peptide receptor 2 (Npr2), and the cGMP-dependent kinase

48 produced by the guanylyl cyclase natriuretic peptide receptor 2 (NPR2).

49 librium on chromosome 13 near relaxin family peptide receptor 2 (RXFP2) were associated with HbA(1c)

50 INSL3 receptor, relaxin/insulin-like family peptide receptor 2 (RXFP2).

51 interaction with relaxin/insulin-like family peptide receptor 2 (RXFP2).

52 within a single gene: vasoactive intestinal peptide receptor 2 (VIPR2).

53 ulation, a GPCR called vasoactive intestinal peptide receptor 2 (VPAC2) is shed, rather than being in

54 Vasoactive intestinal peptide receptor 2 can elicit immune transformation in a

55 Cs isolated from relaxin/insulin-like family peptide receptor 2 gene (Rxfp2) knockout and wild-type m

56 othelial-bound cathelicidin activates formyl-peptide receptor 2 on classical monocytes, resulting in

57 Formyl peptide receptor 2 regulates monocyte recruitment to pro

58 via the guanylate cyclase NPR2 (natriuretic peptide receptor 2) and not the G-protein-coupled cleara

59 tion of ALX/FPR2 (lipoxin A4 receptor/formyl peptide receptor 2) expression.

60 2 (FPR2/ALX) and in mFPR2(-/-) (mouse formyl peptide receptor 2) mice lacking the mouse homolog of hu

61 rway epithelial cells in an ALX/FPR2 (formyl peptide receptor 2) receptor-dependent manner.

62 riuretic peptide A and vasoactive intestinal peptide receptor 2, and a novel mineralocorticoid recept

63 , namely protein phosphatase 5 (PP5), formyl peptide receptor 2, and annexin 1.

64 We investigated airway levels of formyl peptide receptor 2-lipoxin receptor (FPR2/ALXR), LXA4, a

65 n by experiments with DCs lacking the formyl peptide receptor 2.

66 Here we tested whether the formyl-peptide receptor 2/3 (Fpr2/3)--ortholog to human FPR2/AL

67 ested whether the lipoxin A4 receptor formyl-peptide receptor 2/3 (Fpr2/3; ortholog to human FPR2/lip

68 ecific binding to the AnxA1 receptor (formyl peptide receptor 2/Lipoxin A4 receptor [FPR2/ALX]; IC50

69 LL-37, via formyl peptide receptor-2 (FPR-2), triggered the release of cys

70 -4 receptor, the Smoothened receptor, formyl peptide receptor-2 (FPR2), the relaxin receptor (LGR7),

71 rfering RNA-induced knockdown of LXA4 formyl peptide receptor-2 (FPR2/ALX) and in mFPR2(-/-) (mouse f

72 Formyl peptide receptor 3 (Fpr3, also known as Fpr-rs1) is a G

73 Relaxin family peptide receptor 3 (RXFP3) signaling in the BNST has bee

74 er in allergy to tropomyosins and the formyl peptide receptor 3 in allergy to lipocalins are outstand

75 coupled clearance receptor NPR3 (natriuretic peptide receptor 3).

76 The primary role of natriuretic peptide receptor-3 (NPR3) or NPR-C is in the clearance o

77 concentration by binding to its natriuretic peptide receptor A (NPRA) receptor and, in turn, by acti

78 nylyl cyclase 1 (RetGC1) but not natriuretic peptide receptor A (NPRA).

79 ion between ANP and its receptor natriuretic peptide receptor A and reduces intracellular cGMP levels

80 n-releasing peptide receptor and natriuretic peptide receptor A by genetic approaches or toxins in mi

81 The intracellular segment of a natriuretic peptide receptor A guanylyl cyclase failed to bind GCAPs

82 or the interaction of human anti-natriuretic peptide receptor A IgG4 with the neonatal Fc receptor, F

83 trin-releasing peptide receptor, natriuretic peptide receptor A, neuromedin B receptor, and sst2A.

84 228P), an antibody targeting the natriuretic peptide receptor A, show a previously unrecognized type

85 de WKYMVm, a selective agonist of the formyl peptide receptor, a 2-fold increase in leukocyte emigrat

86 e (ANP) binds guanylyl cyclase-A/natriuretic peptide receptor-A (GC-A/NPRA) and produces the intracel

87 delineate the mechanisms of GC-A/natriuretic peptide receptor-A (GC-A/NPRA) gene (Npr1) expression in

88 ANP acting through natriuretic peptide receptor-A (NPRA) lowers blood pressure and bloo

89 Npr1 (encoding guanylyl cyclase/natriuretic peptide receptor-A, GC-A/NPRA) gene-knockout (0-copy; Np

90 Peptide receptor affinities were seen to be as low as 50

91 Several glucagon-like peptide receptor agonists (GLP-1RA) and sodium-glucose c

92 The plant RLK FERONIA is a peptide receptor and has been implicated in plant growth

93 The prolactin-releasing peptide receptor and its bioactive RF-amide peptide (PrR

94 Blocking gastrin-releasing peptide receptor and natriuretic peptide receptor A by g

95 PRRT) is a type of radiotherapy that targets peptide receptors and is typically used for neuroendocri

96 oral, small-molecule calcitonin gene-related peptide receptor antagonist for acute migraine treatment

97 attack with the oral calcitonin gene-related peptide receptor antagonist rimegepant resulted in a hig

98 Rimegepant is a calcitonin gene-related peptide receptor antagonist that has shown efficacy and

99 red, small-molecule, calcitonin gene-related peptide receptor antagonist that may be effective in acu

100 brogepant is an oral calcitonin gene-related peptide receptor antagonist under investigation for acut

101 nt, a small molecule calcitonin gene-related peptide receptor antagonist, has shown efficacy in the a

102 ts, and the gepants: calcitonin gene-related peptide receptor antagonists, in a preclinical model of

103 Formyl-peptide receptors are highly expressed on neutrophils an

104 obably the first of a long list, as multiple peptide receptors are now recognized as potential target

105 cyclase B (GC-B), also known as natriuretic peptide receptor B or NPR2, stimulates long bone growth,

106 The gastrin-releasing peptide receptor (BB2r) is overexpressed in a variety of

107 r-targeted agents, such as gastrin-releasing peptide receptor (BB2r)-targeted peptides, have been inv

108 trial myocytes from wild-type or natriuretic peptide receptor C knockout (NPR-C(-/-)) mice.

109 Moreover, we identified natriuretic peptide receptor-C (NPR-C) as the cognate receptor that

110 the potential role of an NPR-C (natriuretic peptide receptor-C) in atrial fibrosis and the role of a

111 c NP receptors, including NPR-C (natriuretic peptide receptor-C), are cardioprotective hormones that

112 The capa peptide receptor, capaR (CG14575), is a G-protein couple

113 , as it was distinct from atrial natriuretic peptide receptor-cGMP-PKG-RyR2 Ser-2808 signaling and in

114 rtner, c-Fos, and therefore designed a c-Fos peptide receptor chemically modified to incorporate a th

115 trategy to improve the treatment efficacy of peptide receptor chemoradionuclide therapy in NET.

116 eutic efficacy might be further increased by peptide receptor chemoradionuclide therapy.

117 and ECL3, which can orient and stabilize the peptide-receptor complex.

118 ding a complete conformational model for the peptide-receptor complex.

119 crine system by combinations of synaptic and peptide-receptor connections.

120 , but not nonclassical monocytes in a formyl-peptide receptor-dependent manner.

121 revious studies showed that the delta-opioid peptide receptor (DOP-R) is dynamically regulated by exp

122 yl cyclase-A (GC-A) signaling, a natriuretic peptide receptor, exerts renoprotective effects by stimu

123 eceptor, an orthologue of the Drosophila sex peptide receptor, expressed in neighboring apical organ

124 ese effects, whereas recognition by N-formyl peptide receptor family members was dispensable.

125 a member of the chemotactic GPCR-7TM formyl peptide receptor family, whose principle function is in

126 ion and selectivity mechanisms of the formyl peptide receptor family.

127 dy that inhibits the calcitonin gene-related peptide receptor, for the prevention of episodic migrain

128 s, suggesting that this peptide binds formyl peptide receptor (FPR) 2.

129 xert their function by binding to the formyl peptide receptor (FPR) 2.

130 ogenous anti-inflammatory circuit via formyl peptide receptor (FPR) 2/lipoxin receptor (ALX) (Fpr2/3

131 ystemic administration of Boc2, a formylated peptide receptor (fpr) antagonist, abrogated the peptide

132 Innate immune chemoreceptors of the formyl peptide receptor (Fpr) family are expressed by vomeronas

133 The formyl peptide receptor (Fpr) family is well known for its cont

134 ein-coupled receptor belonging to the formyl peptide receptor (FPR) family, conveys the biological fu

135 The formyl peptide receptor (FPR) on neutrophils, which binds to fo

136 ophils in a dose-dependent manner via formyl peptide receptor (FPR) stimulation.

137 nduces calcium and chemotaxis through formyl peptide receptor (FPR)2/ALX, whereas its D-stereoisomer

138 canonical GRK that phosphorylated the formyl peptide receptor FPR1 and facilitated neutrophil migrati

139 r pharmacological inhibition of the N-formyl peptide receptor Fpr1 leads to increased insulin levels

140 Mouse neutrophils lacking formyl peptide receptors (Fpr1/2(-/-)) are defective in the pha

141 casts depends on the high-affinity N-formyl peptide receptor, Fpr1.

142 The neutrophil formyl peptide receptors, FPR1 and FPR2, play critical roles fo

143 15-epi-LXA4 activated formyl peptide receptor (FPR2) and GPR120 on alternative macrop

144 N-formyl peptide receptors (FPRs) are critical regulators of host

145 Formyl peptide receptors (FPRs) are G-protein-coupled receptors

146 Formyl-peptide receptors (FPRs) are important pattern recogniti

147 nt work showed that G-protein-coupled formyl peptide receptors (FPRs) directly mediate neutrophil pha

148 N-formyl peptide receptors (FPRs) serve as phagocyte pattern-reco

149 f such receptor-ligand pairs involves formyl peptide receptors (FPRs) that have been shown to influen

150 ion of neuronal specificity by immune formyl peptide receptors (Fprs).

151 gnificant difference in expression of formyl peptide receptors (FPRs).

152 mRNAs for annexin A1 (AnxA1) and the formyl peptide receptors [(Fprs) 1, 2, and 3], a loss of lipid

153 osmoregulatory functions in brain, where SCT peptide/receptor function is required for ANGII action,

154 Here, we show that opioid peptide receptors, GPCRs that mediate highly sensitive p

155 ICK1 interaction partner prolactin-releasing peptide receptor (GPR10).

156 radioligands targeting the gastrin-releasing peptide receptor (GRP-R) might offer a specific method f

157 ntly introduced the potent gastrin-releasing peptide receptor (GRPR) antagonist (68)Ga-SB3 ((68)Ga-DO

158 state cancer, radiolabeled gastrin-releasing peptide receptor (GRPr) antagonists have yielded promisi

159 stablish that NK1R and the gastrin-releasing peptide receptor (GRPR) are coexpressed within a subpopu

160 conjugate affinity for the gastrin releasing peptide receptor (GRPR) as determined against [(125)I-Ty

161 ause overexpression of the gastrin-releasing peptide receptor (GRPR) has been reported on various can

162 urons comprise a subset of gastrin-releasing peptide receptor (GRPR) interneurons and are thus positi

163 The gastrin-releasing peptide receptor (GRPR) is a well-known target in cancer

164 Gastrin releasing peptide receptor (GRPR) is an attractive target for OSCC

165 Gastrin-releasing peptide receptor (GRPR) is overexpressed in human prosta

166 The gastrin-releasing peptide receptor (GRPR) is overexpressed in human prosta

167 The gastrin-releasing peptide receptor (GRPr) is overexpressed in prostate can

168 of evidence suggests that gastrin-releasing peptide receptor (GRPR) might be a valuable target in br

169 Consistently, ablation of gastrin-releasing peptide receptor (GRPR) neurons, which are essential for

170 Ablation of gastrin-releasing peptide receptor (GRPR) or GRPR neurons in the SCN aboli

171 spinal neurons expressing gastrin releasing peptide receptor (GRPR) primarily comprise excitatory in

172 ation, depends on CGRP and gastrin-releasing peptide receptor (GRPR) transmission because pharmacolog

173 and BBS-cognate receptor (gastrin-releasing peptide receptor (GRPR)).

174 with high affinity for the gastrin-releasing peptide receptor (GRPr), a receptor that is overexpresse

175 Its receptor, gastrin-releasing peptide receptor (GRPR), is expressed by various cell ty

176 their affinity toward the gastrin releasing peptide receptor (GRPr), metabolic stability in blood pl

177 Because expression of the gastrin-releasing peptide receptor (GRPR), somatostatin receptor 2 (SSTR2)

178 r diagnosis and therapy of gastrin releasing peptide receptor (GRPR)-expressing tumors.

179 or antagonist that targets gastrin-releasing peptide receptor (GRPr).

180 armacophores targeting the gastrin-releasing peptide receptor (GRPR).

181 Gastrin-releasing peptide receptors (GRPrs) are overexpressed on a variety

182 Gastrin-releasing peptide receptors (GRPRs) are potential molecular imagin

183 Gastrin-releasing peptide receptors (GRPRs) expressed on human tumors can

184 Calcitonin gene-related peptide receptor has been implicated in the pathogenesis

185 nstrating the potential of gastrin-releasing-peptide receptor imaging.

186 the expression of PSMA and gastrin-releasing peptide receptors in different types of prostate cancer.

187 Stimulation of formyl peptide receptors increases the mitochondrial membrane p

188 TP production and requires an initial formyl peptide receptor-induced Ca(2+) signal that triggers mit

189 ch as naproxen and a calcitonin gene-related peptide receptor inhibitor, olcegepant, were less effect

190 re previously reported to function as formyl peptide receptor inhibitors.

191 Further we show that insulin-like peptide receptor (INSR) and forkhead box protein O (FoxO

192 A direct peptide-receptor interaction is supported by specific bi

193 novel insights into the oxytocin/vasopressin peptide-receptor interaction, which led to the identific

194 tide GPCRs has advanced our understanding of peptide-receptor interactions and fueled interest in cor

195 For testing high-affinity peptide-receptor interactions in the plasma membrane of

196 ool for the validation and quantification of peptide-receptor interactions in their natural cellular

197 egions may not give a complete reflection of peptide/receptor interactions and should be combined wit

198 dditional experimental constraints to reveal peptide/receptor interactions occurring in the dynamic,

199 We show that groups in which the sex-peptide-receptor is absent in females (SPR-) have higher

200 Cell-cell communication mediated by secreted peptides, receptor kinases, and downstream mitogen-activ

201 Four arginine-containing peptide receptor ligands (angiotensin II, neurotensin(8-

202 state-specific membrane or gastrin-releasing peptide receptor ligands for the imaging of prostate can

203 of cathelicidin are mediated through formyl peptide receptor-like 1 (FPRL1), we hypothesize that CSA

204 ule formation, suggesting that CRA2 is a CEP peptide receptor mediating both organogenesis programs.

205 ptides for itch, including gastrin-releasing peptide receptor, natriuretic peptide receptor A, neurom

206 nd 1980s, the nociceptin/orphanin FQ (N/OFQ) peptide receptor (NOP, also known as ORL-1) was discover

207 did not differentially modulate natriuretic peptide receptor (NPR)-A/B activity with respect to T223

208 helium-specific CNP(-/-), global natriuretic peptide receptor (NPR)-B(-/-) and NPR-C(-/-) animals, an

209 and the guanylate cyclase-linked natriuretic peptide receptors Npr1 and Npr2 are functionally redunda

210 iculate guanylate cyclase-linked natriuretic peptide receptors Npr1 and Npr2, and activation of prote

211 bilizing G protein-coupled receptors (formyl peptide receptor, P2Y2 purinergic receptor, and calcium-

212 We experimentally analyzed one peptide-receptor pair and found that a neuropeptide can

213 Analysis of peptide-receptor pairs in spatially mapped single-cell t

214 Gastrin-releasing peptide receptors, part of the bombesin family, are over

215 maging may be used to monitor the effects of peptide receptor radiolabeled targeted therapy in patien

216 ion due to (68)Ga-DOTATATE was initiation of peptide receptor radionuclide therapy (14 patients, 27.4

217 reatic neuroendocrine tumors (GEP NET) after peptide receptor radionuclide therapy (PRRT) are still l

218 Peptide receptor radionuclide therapy (PRRT) has become

219 Peptide receptor radionuclide therapy (PRRT) has been us

220 ty after internal radiation exposure through peptide receptor radionuclide therapy (PRRT) has not yet

221 ker, the inflammation-based index (IBI), for peptide receptor radionuclide therapy (PRRT) in neuroend

222 ker, the inflammation-based index (IBI), for peptide receptor radionuclide therapy (PRRT) in neuroend

223 Peptide receptor radionuclide therapy (PRRT) is a promis

224 Peptide receptor radionuclide therapy (PRRT) is a type o

225 ((177)Lu) DOTA-0-Tyr3-Octreotate (DOTATATE) peptide receptor radionuclide therapy (PRRT) is an effec

226 Peptide receptor radionuclide therapy (PRRT) is an effec

227 Peptide receptor radionuclide therapy (PRRT) is an impor

228 Peptide receptor radionuclide therapy (PRRT) may induce

229 date, limited data are available concerning peptide receptor radionuclide therapy (PRRT) of grade 3

230 iation with (177)Lu-DOTA-octreotate (LuTate) peptide receptor radionuclide therapy (PRRT) of neuroend

231 Somatostatin receptor (SSTR)-targeted peptide receptor radionuclide therapy (PRRT) represents

232 Peptide receptor radionuclide therapy (PRRT) using radio

233 Peptide receptor radionuclide therapy (PRRT) using radio

234 In addition, OS in relation to peptide receptor radionuclide therapy (PRRT) was analyze

235 Peptide receptor radionuclide therapy (PRRT) with (177)L

236 ntraarterial administration of (90)Y-DOTATOC peptide receptor radionuclide therapy (PRRT) would incre

237 Peptide receptor radionuclide therapy (PRRT), such as (1

238 ncreatic neuroendocrine tumor, responding to peptide receptor radionuclide therapy (PRRT).

239 crucial for individualized treatment during peptide receptor radionuclide therapy (PRRT).

240 ression may be the dose-limiting toxicity in peptide receptor radionuclide therapy (PRRT).

241 in analogs may lead to nephrotoxicity during peptide receptor radionuclide therapy (PRRT).

242 n of somatostatin receptors qualifies it for peptide receptor radionuclide therapy (PRRT).

243 as a prerequisite for the administration of peptide receptor radionuclide therapy (PRRT).

244 Peptide receptor scintigraphy and peptide receptor radionuclide therapy are successfully a

245 s might further improve the safety window of peptide receptor radionuclide therapy by reducing the li

246 Conclusion: Peptide receptor radionuclide therapy can lead to bowel

247 Peptide receptor radionuclide therapy in advanced neuroe

248 Further study of peptide receptor radionuclide therapy in patients with s

249 I and III studies; delineate the position of peptide receptor radionuclide therapy in the therapeutic

250 Peptide receptor radionuclide therapy is a new frontier

251 Peptide receptor radionuclide therapy is a treatment for

252 opancreatic neuroendocrine tumors, access to peptide receptor radionuclide therapy is increasing.

253 ostics are peptide receptor scintigraphy and peptide receptor radionuclide therapy of neuroendocrine

254 ht enhance peptide receptor scintigraphy and peptide receptor radionuclide therapy of neuroendocrine

255 Dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTA

256 uroendocrine tumors (NETs) can be treated by peptide receptor radionuclide therapy using radiolabeled

257 Peptide receptor scintigraphy and peptide receptor radionuclide therapy using radiolabeled

258 In peptide receptor radionuclide therapy with (90)Y-labeled

259 ment in recent years was the introduction of peptide receptor radionuclide therapy with radiolabeled

260 However, antiangiogenic drugs, peptide receptor radionuclide therapy, and targeted agen

261 for prospective dosimetry for (67)Cu-SARTATE peptide receptor radionuclide therapy, and the half-life

262 systemic treatment of advanced disease with peptide receptor radionuclide therapy, biotherapy, chemo

263 Through diagnostic imaging and peptide receptor radionuclide therapy, nuclear medicine

264 tients who will qualify for and benefit from peptide receptor radionuclide therapy.

265 herapy for differentiated thyroid cancer and peptide receptor radionuclide therapy.

266 well-known target for molecular imaging and peptide receptor radionuclide therapy.

267 easible and may have a significant impact on peptide receptor radionuclide therapy.

268 cidence of intestinal obstruction related to peptide receptor radionuclide therapy.

269 determining the suitability of patients for peptide receptor radionuclide therapy.

270 ice and was suggested as a radioprotector in peptide receptor radionuclide therapy.

271 d be achieved if exendin were to be used for peptide receptor radionuclide therapy.

272 P = 0.002), and type of therapy (medical vs. peptide receptor radionuclide therapy: 16.0 vs. 26.0 mo;

273 quency of false-positive recommendations for peptide-receptor radionuclide therapy occurred in observ

274 , image-based recommendations for or against peptide-receptor radionuclide therapy require experience

275 Interpretations of appropriateness for peptide-receptor radionuclide therapy varied more signif

276 Peptide receptor radiotherapy using (177)Lu-labeled soma

277 E PET/CT correctly identified 3 patients for peptide-receptor radiotherapy incorrectly classified by

278 The peptide-receptor relationships determine the specificiti

279 heart failure, activates the relaxin family peptide receptor (RXFP1), which is a class A G-protein-c

280 he highly conserved family of relaxin family peptide receptors (RXFPs), mediates the checkpoint funct

281 most successful examples of theranostics are peptide receptor scintigraphy and peptide receptor radio

282 Peptide receptor scintigraphy and peptide receptor radio

283 SSTR antagonists such as JR11 might enhance peptide receptor scintigraphy and peptide receptor radio

284 Peptide receptor scintigraphy and peptide receptor radio

285 Here, we demonstrate that the sex peptide receptor (SPR) of Drosophila, known for its role

286 and p38 MAPK signaling in response to formyl peptide receptor stimulation.

287 and cAMP accumulation in response to formyl peptide receptor stimulation.

288 urther reveal a feedback circuit between the peptide-receptor system and auxin response as a mechanis

289 The underlying biology of these peptide/receptor systems, their physiologic and patholog

290 human cancers, providing the opportunity for peptide receptor targeting via radiolabeled bombesin-bas

291 Peptides such as gastrin-releasing peptide receptors targeting radiopharmaceuticals are sma

292 A new family of peptide receptors, the incretin receptor family, overexp

293 ceptors, such as the calcitonin gene-related peptide receptor, to the plasma membrane.

294 Formyl-peptide receptor type 2 (FPR2), also called ALX (the lip

295 Formyl-peptide receptor type 2 (FPR2; also called ALX because i

296 2, consistent with the idea that natriuretic peptide receptor type 2 (NPR2) signaling inhibits the ac

297 ratio of the signaling receptor, natriuretic peptide receptor type A, to the clearance receptor, nprc

298 ology for predicting binding scores of small peptide receptors vs. volatile compounds is proposed.

299 In a screen of all 49 predicted Ae. aegypti peptide receptors, we identified NPY-like receptor 7 (NP

300 and an antagonist for the gastrin-releasing peptide receptor were found to have excellent tumor-targ